康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗非缺血性视网膜分支静脉阻塞继发黄斑水肿的临床效果  

Clinical Effect of Intravitreal Injection of Conbercept Combined with Macular Grid Laser Photocoagulation for Macular Edema Secondary to Non-ischemic Branch Retinal Vein Occlusion

作　　者：吴伟柯 WU Weike(Department of Ophthalmology,Yixing Hospital of Traditional Chinese Medicine,Yixing 214200,Jiangsu,China)

机构地区：[1]宜兴市中医医院眼科,江苏宜兴214200

出　　处：《世界复合医学（中英文）》2024年第9期168-171,共4页World Journal of Complex Medicine

摘　　要：目的分析非缺血性视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)继发黄斑水肿(macular edema,ME)患者采用康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗的效果。方法选择2020年1月—2023年12月宜兴市中医医院收治的100例非缺血性BRVO继发ME患者为研究对象,根据不同的治疗方法分为对照组(应用玻璃体腔注射康柏西普治疗)及研究组(在对照组基础上增加黄斑格栅样激光光凝治疗),各50例。比较两组治疗效果、血清因子、不良反应发生率。结果干预前,两组最佳矫正视力(best corrected visual acuity,BCVA)及黄斑中心凹厚度(center macular thickness,CMT)比较,差异无统计学意义(P均>0.05)。干预后,两组的BCVA及CMT均得到改善,且研究组优于对照组,差异有统计学意义(P均<0.05)。干预后,研究组的血管内皮生长因子及人基质细胞衍生因子-1水平均低于对照组,差异有统计学意义(P均<0.05)。研究组的不良反应发生率为2.00%(1/50),低于对照组的14.00%(7/50),差异有统计学意义(χ^(2)=4.891,P<0.05)。结论康柏西普玻璃体腔注射联合黄斑格栅样激光光凝治疗非缺血性BRVO继发ME患者疗效显著,安全性较高。Objective To analyze the effect of intravitreal injection of conbercept combined with laser photocoagulation in patients with macular edema(ME)secondary to non-ischemic branch retinal vein occlusion(BRVO).Methods A total of 100 patients with ME secondary to non-ischemic BRVO admitted to Yixing Hospital of Traditional Chinese Medicine from January 2020 to December 2023 were selected as the research objects.According to different treatment methods,they were divided into control group(treated with intravitreal injection of conbercept alone)and study group(treated with macular grille-like laser photocoagulation on the basis of the control group),with 50 cases in each group.The therapeutic effect,serum factor and incidence of adverse reactions were compared between the two groups.Results Before intervention,there were no significant difference in best corrected visual acuity(BCVA)and center macular thickness(CMT)between the two groups(both P>0.05).After intervention,BCVA and CMT were improved in two groups,and the study group was better than the control group,the differences were statistically significant(both P<0.05).The levels of vascular endothelial growth factor and stromal cell-derived factor-1 in the study group were lower than those in the control group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in the study group was 2.00%(1/50),which was lower than that 14.00%(7/50)in the control group,and the difference was statistically significant(χ^(2)=4.891,P<0.05).Conclusion Intravitreal injection of conbercept combined with macular grid laser photocoagulation is effective and safe in the treatment of ME secondary to non-ischemic BRVO.

关 键 词：非缺血性视网膜分支静脉阻塞 黄斑水肿 临床效果 

分 类 号：R774[医药卫生—眼科]